Investing

Also, Neurophet will tap into Roche's data to further improve its brain scan analysis AI.

The company said it plans to develop its new Chai‑2 platform to design, from square one, completely new antibodies for viruses and cancer.

The company intends to partner with healthcare, biopharmaceutical, medical device and diagnostic companies.

The company aims to help providers secure stable pricing and access products and services for patients seeking reproductive and sexual healthcare.

The company will use the funds to scale its reach within the U.S. and to expand access to its offerings globally.

The company said it plans to expand U.S. access to its services while growing its pipeline to include additional cardiac conditions and new distribution channels.

The company, which uses AI to help companies manage value-based care contracts, will use the funds to grow its team and scale its platform.

The funding comes a year after the company secured $70 million in a Series B funding round.

Also, OMRON in Singapore has launched a new medical device plan featuring AI-driven recommendations for self-management of chronic diseases.

When it comes to making strategic AI investment deals, companies need to articulate their competitive advantage and how they view the market around them, says Jason Smith, venture acceleration fellow at MATTER.